OPERATING-PROFIT FORECAST: The company is expected to post business operating profit of 2.37 billion euros, according to Vara Research. It reported business operating profit---one of the company's ...

A federal judge trimmed a lawsuit that accuses Sanofi of cornering the market for an injectable form of a diabetes drug, ...

Sanofi has reported mixed phase 3 data on amlitelimab, further muddying the prospec | Sanofi has reported mixed phase 3 data ...

Sanofi (NASDAQ: SNY) is preparing to release its quarterly earnings on Thursday, 2026-01-29. Here's a brief overview of what ...

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis (AD) candidate amlitelimab after reporting ...

But while the rankings held steady, the operating environment has changed quickly to reinforce the value of being in good ...

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...

Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase ...

Ocular Therapeutix’s lead asset is Axpaxli, being developed for wet age-related macular degeneration. A Phase III study is ...

Sanofi may rebid for Ocular Therapeutix, Inc. to boost retinal therapeutics ahead of Dupixent patent expiry. Click for more ...

The mixed data from the Phase III COAST 2 trial follows an underwhelming data drop from COAST 1 in September that Leerink ...

Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U ...